Effect of an herbal preparation, STW 5, in an acute model of reflux oesophagitis in rats

Journal of Pharmacological Sciences

Volumn 113, Issue 2, 2010, Pages 134-142

  Abdel Aziz, Heba ^a   Zaki, Hala F ^b   Neuhuber, Winfried ^c   Kelber, Olaf ^d   Weiser, Dieter ^d   Khayyal, Mohamed T ^b  

^a Heliopolis University for Sustainable Development   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Steigerwald Arzneimittelwerk GmbH   (Germany)

Author keywords

Gastro oesophageal reflux disease; Pyloric ligation; Rat model; Reflux oesophagitis; STW 5

Indexed keywords

HERBACEOUS AGENT; IBEROGAST; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PANTOPRAZOLE; STW 5; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; ESOPHAGUS PH; ESOPHAGUS ULCER; HISTOPATHOLOGY; INFLAMMATION; MALE; NONHUMAN; RAT; REFLUX ESOPHAGITIS; TISSUE HOMOGENATE; ANIMAL; DISEASE MODEL; GASTROESOPHAGEAL REFLUX; LIGATION; PHYTOTHERAPY; STOMACH ANTRUM; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GASTROESOPHAGEAL REFLUX; INFLAMMATION MEDIATORS; LIGATION; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PYLORIC ANTRUM; RATS; RATS, WISTAR;

EID: 77953834647     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09355FP     Document Type: Article

References (53)

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-717.
2. Boeckxstaens GE. Emerging drugs for gastro-oesophageal reflux disease. Expert Opin Emerg Drugs. 2009;14:481-491.
3. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903.
4. Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastrooesophageal reflux disease (GERD). Int J Clin Pract. 2005;59:346-355.
5. Pereira Rde S. Regression of gastro-esophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: comparison with omeprazole. J Pineal Res. 2006;41:195-200.
6. Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19:62-68.
7. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, et al. Gastro-oesophageal reflux might cause oesophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776-1784.
8. Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil. 2009;21:832-856.
9. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci. 2006;51:2113-2120.
10. Quigley EMM, Keohane J. Dyspepsia. Curr Opin Gastroenterol. 2008;24:692-697.
11. Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006;24:475-492.
12. Stanghellini V, Barbara G, Cogliandro R, Salvioli B, Cremon C, de Giorgio R, et al. Overlap between GERD and IBS: irrefutable but subtle. J Clin Gastroenterol. 2007;41:S114-S117.
13. Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72-78.
14. Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine. 2006;13:SV12-SV19.
15. Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine. 2006;13:SV20-SV35.
16. Allescher HD, Wagner H. STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome. Wien Med Wochenschr. 2007;157:301-307.
17. Gundermann KJ, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv Ther. 2003;20:43-49.
18. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;469:45-52.
19. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a doubleblind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19:271-279.
20. Madisch A, von Arnim U, Müller J, Vinson B, Zeller K, Malfertheiner P. Herbal preparation STW 5 improved quality of life in patients with functional dyspepsia - results of a placebocontrolled trial. Gastroenterology. 2008;134:A422.
21. Rösch W, Vinson B, Sassin I. A randomized clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002;40:401-408.
22. Rösch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine. 2006;13:SV114-SV121.
23. Khayyal MT, El-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, et al. Antiulcerogenic effect of some gastrointestinal acting plant extracts and their combination. Arzneimittelforschung. 2001;51:545-553.
24. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine. 2006;13:SV56-SV66.
25. Hohenester B, Rühl A, Kelber O, Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil. 2004;16:765-773.
26. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol. 2004;102:1276-1283.
27. Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, et al. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil. 2004;16:759-764.
28. Müller MH, Liu CY, Glatzle J, Weiser D, Kelber O, Enck P, et al. STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine. Phytomedicine. 2006;13:SV100-SV106.
29. Schemann M, Krüger D, Gruber L, Angay O, Rohn M, Zeller F, et al. Action profile of the phytomedicine STW 5 suggests novel indications. Neurogastroenterol Motil. 2008;20:S95.
30. Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70:S4-S19.
31. 2 in a rat model of oesophagitis mediated by EP1 receptors: relation to pepsin secretion. Digestion. 2005;72:109-118.
32. Uchiyama M, Mihara M. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271-278.
33. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
34. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100.
35. Chapman DB, Rees CJ, Lippert D, Sataloff RT, Wright SC Jr. Adverse effects of long-term proton pump inhibitor use: a review for the otolaryngologist. J Voice. 2010 (in press).
36. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80-87.
37. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473-479.
38. Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64:9-13.
39. Talley NJ. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust. 2009;190:109-110.
40. Madisch A, Mueller MH, Vinson B, Weiser D. Herbal preparation STW 5 significantly improved concomitant reflux symptoms in patients with functional dyspepsia - a subgroup analysis of placebo-controlled trials. Gastroenterology. 2008;134:A422.
41. Yamaguchi T, Yoshida N, Tomatsuri N, Takayama R, Katada K, Takagi T, et al. Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux oesophagitis in rats. Int J Mol Med. 2005;16:71-77.
42. Shin YK, Sohn UD, Choi MS, Kum C, Sim SS, Lee MY. Effects of rutin and harmaline on rat reflux oesophagitis. Auton Autacoid Pharmacol. 2002;22:47-55.
43. Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut. 1995;37:168-173.
44. Wetscher GJ, Hinder RA, Klingler P, Gadenstätter M, Perdikis G, Hinder PR. Reflux oesophagitis in humans is a free radical event. Dis Oesophagus. 1997;10:29-32.
45. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine. 2006;13:SV36-SV44.
46. Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S, Weiser D, et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine. 2006;13:SV45-SV50.
47. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96:229-245.
48. Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and α - tocopherol, an antioxidant vitamin on experimental reflux oesophagitis in rats. Eur J Pharmacol. 2008;589:233-238.
49. Bonaterra GA, Kelber O, Kinscherf R, Traut U, Seitz S, Weiser D, et al. Anti-inflammatory and anti-cancer effects of the phytomedicine STW 5 and its components in vitro. Planta Med. 2008;74:PA295.
50. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasiadysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257-1264.
51. Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett's metaplasia? Curr Opin Pharmacol. 2009;9:721-726.
52. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491-500.
53. Nieber K, Michael S, Vinson B, Kelber O. Anti-inflammatory pathways involved in the multi-target action of STW5 (Iberogast®). Neurogastroenterol Motil. 2009;21:S77-S78.